Performance of the BioPlex 2200 Multiplexing Immunoassay Platform for the Detection of Herpes Simplex Virus Type 2 Specific Antibodies in African Settings | Zendy

Jérôme LeGoff | Zendy; Gérard Grésenguet | Zendy; Chrysostome Gody | Zendy; Jean De Dieu Longo | Zendy; Nzambi Khonde | Zendy; Helen A. Weiss | Zendy; Philippe Mayaud | Zendy; Laurent Bélec | Zendy

Open Access

Performance of the BioPlex 2200 Multiplexing Immunoassay Platform for the Detection of Herpes Simplex Virus Type 2 Specific Antibodies in African Settings

Author(s) -

Jérôme LeGoff,

Gérard Grésenguet,

Chrysostome Gody,

Jean De Dieu Longo,

Nzambi Khonde,

Helen A. Weiss,

Philippe Mayaud,

Laurent Bélec

Publication year - 2011

Publication title -

clinical and vaccine immunology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.649

H-Index - 77

eISSN - 1556-6811

pISSN - 1556-679X

DOI - 10.1128/cvi.05003-11

Subject(s) - herpes simplex virus , immunoassay , virology , antibody , multiplexing , virus , computer science , immunology , medicine , telecommunications

The BioPlex platform was evaluated for the detection of herpes simplex virus 2 (HSV-2) antibodies in sub-Saharan Africa individuals in comparison to clinicovirological standards and compared to HerpeSelect. The sensitivities and specificities were, respectively, 88.9% and 93.5% for BioPlex and 89.9% and 92.7% for HerpeSelect. The agreement between both assays was 95.7%.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research